3569 |
Rethinking DAPT Duration with Smarter DES: Personalized vs. Generalized Strategy |
Davide Capodanno |
Apr. 28. 18 |
3568 |
Proven Secondary Prevention Effect of Ticagrelor from 2017 ESC DAPT Guideline and PEGASUS TIMI-54 |
Joo-Yong Hahn |
Apr. 28. 18 |
3567 |
High Bleeding Risk Patients with DES: Insights from SENIOR and LEADER-FREE Trials |
Marie-Claude Morice |
Apr. 28. 18 |
3566 |
Contemporary Drug Eluting Stents Are Different.: How I Choose DES Type According to Patient/Lesion Features |
Andrejs Erglis |
Apr. 28. 18 |
3565 |
¡°Clinical Outcomes with HBR¡± – LEADERS FREE JAPAN and Angioscopic Findings |
Shimpei Nakatani |
Apr. 28. 18 |
3564 |
\"Biolimus A9 and Its Value\"- Amazing Efficacy of Biolimus A9– Pathologic Findings |
Gaku Nakazawa |
Apr. 28. 18 |
3563 |
\"How Do We Manage HBR Patients?\"- Polymer-Free DES in Elderly Patients |
Byeong-Keuk Kim |
Apr. 28. 18 |
3562 |
\"Who Are HBR Patients?\" - Identification of HBR Patients in Clinical Practice |
Dominick J. Angiolillo |
Apr. 28. 18 |
3561 |
Comparative Outcomes of Contemporary DES in Real-World: Is There Difference? |
Duk-Woo Park |
Apr. 28. 18 |
3560 |
Driving a Major Change in SFA Intervention |
Masahiko Fujihara |
Apr. 28. 18 |